All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 27, 2021
See today's BioWorld
Home
» With three debuts in two weeks, HKEX's biotech IPO market remaining strong
To read the full story,
subscribe
or
sign in
.
With three debuts in two weeks, HKEX's biotech IPO market remaining strong
Nov. 1, 2019
By
Elise Mak
No Comments
BEIJING – After Suzhou, China-based
Ascentage Pharma Group International
launched a $53 million IPO on the Hong Kong Stock Exchange (HKEX) Monday,
Tot Biopharm International Co. Ltd.
, also from Suzhou, and
Sinomab Bioscience Ltd.
, of Hong Kong, will also debut on the bourse to reap as much as $87 million and $223.1 million, respectively, in the following two weeks.
BioWorld
Financings